The Continuous Renal Replacement Therapy Market is segmented based on product, and modality. On the basis of product, the market is segmented into CRRT systems, disposables, and dialysates & replacement fluids, in which dialysates and replacement fluids is expected to account for the largest share of the market. This is attributed to the large volume of these products required during CRRT procedures.
Based on modality, the market is segmented into slow continuous ultrafiltration (SCUF), continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF). The CVVH segment is estimated to command the larger share of the global CRRT market due to the wide adoption of this modality among healthcare providers owing to its wide range of advantages (such as removal of solutes in large quantities, easy fluid balance maintenance, and superior outcomes) over other CRRT modalities.
The report covers the market across four major geographies, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Europe is expected to command the largest share of the market in 2017. However, Asia-Pacific is expected to register the highest growth rate during the forecast period due to the large acute kidney injury patient population, high utilization of CRRT in Australia and Japan, and improving healthcare infrastructure across Asian countries.
However, high procedural cost of CRRT and stringent regulatory guidelines for CRRT in North America are the major factors restraining the growth of this market.
The major players in the continuous renal replacement therapy market are Baxter International Inc. (U.S.), Fresenius Medical Care AG & Co. KGaA (Germany), Nikkiso Co., Ltd. (Japan), B. Braun Melsungen AG (Germany), Bellco S.r.l. (Italy), NxStage Medical, Inc. (U.S.), Asahi Kasei Corporation (Japan), Infomed SA (Switzerland), Medica S.p.A. (Italy), and Toray Medical Co., Ltd. (Japan).
PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=246917088
Rising adoption of continuous venovenous hemofiltration (CVVH) among critical care providers, to drive CRRT industry growth during forecast period
Continuous Venovenous Hemofiltration (CVVH)
The widespread adoption of this modality for the treatment of AKI due to the procedural benefits poses such as high filtrate flow in CVVH that enhances the performance of solute removal, highly effective for the removal of large molecules from patients with reduced renal function or kidney failure, solutes can be removed in large quantities while easily maintaining a net zero or even a positive fluid balance in the patient. Furthermore, growing demand of continuous venovenous hemofiltration is augmented by its effectiveness in removing big molecules while maintaining a positive fluid balance in patients and a large number of ongoing research studies and clinical trials to establish the safety and efficacy profile for CRRT products.
Continuous Venovenous Hemodiafiltration (CVVHDF)
In this modality, blood is passed through a hemofilter and a dialysate is injected on the other side of the semi-permeable membrane, combining the filtration and dialysis processes. Positive demand growth of CVVHDF is driven by the key advantages such as better clearance of medium-sized solutes as compared to hemodialysis (due to the combination of hemofiltration with the continuous HD procedure), proper acid-base balance without additional intervention, and a significant reduction in CRRT-related phosphate depletion.
Continuous Venovenous Hemodialysis (CVVHD)
This technique removes solutes by diffusion using dialysates; replacement fluids are not required in this therapy. Effectiveness of this modality in removing small and medium-sized molecules, increasing incidences of acute renal failure and lactic acidosis are the key factors propelling the demand for CVVHD market.
Slow Continuous Ultrafiltration (SCUF)
SCUF primarily removes water from the bloodstream through ultrafiltration. This process removes excess water at a very slow ultrafiltration rate. The modest market share of this segment is mainly due to several factors such as increasing use in resolving fluid overloads, pulmonary edemas, & congestive heart failure; very low adoption owing to insufficiencies in waste clearance considering the severity of patients; and the ultrafiltrate utilized in SCUF is low, which helps in maintaining the stability of a patient’s vital signs and does not have any major side effects.
More Info: https://www.marketsandmarkets.com/Market-Reports/continuous-renal-replacement-therapy-market-246917088.html
